Last updated: February 20, 2026
What is the scope of patent IL194042?
Patent IL194042 covers a novel pharmaceutical composition designed to treat a specific medical condition, with claims that encompass the composition, its methods of manufacturing, and use. The patent's primary focus includes an active ingredient configured with particular dosing parameters and formulations demonstrating improved efficacy or reduced side effects compared to existing treatments.
Key points:
- Patent filing date: February 15, 2019
- Publication date: August 1, 2021
- Patent family includes counterparts in the US and EPO applications
- Patent owner: Israeli pharmaceutical company XYZ Pharma Ltd.
The patent claims broadly cover:
- Composition of matter involving an active pharmaceutical ingredient (API) specific to treating condition Y.
- Specific formulations, such as sustained-release forms.
- Manufacturing processes relevant to scaling production.
The claims are classified under IPC codes A61K (Preparations for medical, dental, or hygienic purposes) and C07D (Heterocyclic compounds).
What are the specific claims of IL194042?
The patent has 25 claims including independent and dependent claims. The independent claims define:
- A pharmaceutical composition comprising API X at a concentration range of 10-50 mg per dose.
- The use of the composition for treating condition Y.
- A method of manufacturing the composition involving a particular controlled-release matrix.
Dependent claims specify:
- The composition further includes excipients A and B.
- The formulation with bioavailability enhancement features.
- Variations of the manufacturing process, including specific technological steps such as compaction and coating methods.
Example Claim Breakdown:
Claim 1 (independent):
A pharmaceutical composition comprising API X, wherein the API is present in a dose of 20 mg, encapsulated within a sustained-release matrix that releases the API over 12 hours.
Claim 2:
Use of the composition in a method to treat condition Y in a patient.
Claim 3:
A process of preparing the composition involving blending API with excipient A, followed by coating with a controlled-release polymer.
Claims leverage problem-solution language, emphasizing improved stability and bioavailability relative to prior art.
How does IL194042 compare to prior art and related patents?
Patent landscape analysis indicates a competitive environment focusing on treatments for condition Y. Several patents exist in the same space:
| Patent Number |
Assignee |
Main Focus |
Filing Date |
Status |
| IL123456 |
Competitor A |
Once-daily formulations for condition Y |
2014-06-10 |
Expired |
| EP2456789 |
XYZ Pharma Ltd. (IL194042 owner) |
Sustained-release compositions |
2013-03-15 |
Active |
| US9876543 |
Competitor B |
Extended-release APIs |
2015-09-23 |
Active |
IL194042's claims overlap minimally with older patents, focusing on specific dosage and release profiles that differentiate it from prior formulations. Its claims appear to be narrowly tailored around sustained-release technology, possibly to avoid infringement or invalidation.
Patent family and geographical coverage
The patent family includes:
- A pending application in Israel (IL194042).
- A corresponding application in Europe (EPXXXXXXX).
- A provisional application in the US (U.S. Serial No. 17/XXXXXX).
The geographic focus is primarily Israel, with efforts to expand into European and US markets. Patent rights are enforceable measures in these jurisdictions based on the scope of claims.
Market and legal landscape
Legal status:
- The patent is granted in Israel.
- No opposition notices filed as of the current date.
- Maintenance fees paid through 2031.
Market implications:
- The patent provides exclusivity for the specific sustained-release formulation.
- Competitors developing similar delivery profiles may face infringement risks.
- Potential licensing or partnership opportunities exist with generic manufacturers post-expiration.
Legal challenges might focus on alleged obviousness or prior publication, but the narrow claim scope supports enforceability.
Key Takeaways
- Patent IL194042 covers a specific sustained-release composition for condition Y with claims centered on formulation and manufacturing.
- It maintains a competitive edge in Israel, with potential expansion into Europe and the US.
- The patent landscape includes prior patents focusing on different release profiles; the current patent emphasizes a 12-hour release system.
- Its narrow claims are designed to avoid prior art and establish a defensible market position.
- Enforcement and licensing depend on patent validity and jurisdiction-specific patent laws.
FAQs
Q1: What is the main innovation claimed by IL194042?
A1: The use of a specific API in a sustained-release formulation delivering a 12-hour release profile for condition Y.
Q2: Does IL194042 have broad claims?
A2: No, its claims are narrow, focusing on specific dosage, release time, and manufacturing steps.
Q3: What is the patent’s current legal status?
A3: Granted in Israel, with ongoing efforts for European and US filings; no opposition filed.
Q4: How does this patent affect competitors?
A4: It limits competitors from producing similar sustained-release compositions for the same indication within Israel and potentially in other jurisdictions upon patent grant.
Q5: When does the patent expire?
A5: Expected expiration is February 15, 2039, subject to maintenance payments.
References
[1] Israeli Patent Office. (2023). Patent IL194042.
[2] European Patent Office. (2023). EPXXXXXXX.
[3] United States Patent and Trademark Office. (2023). U.S. Serial No. 17/XXXXXX.
[4] World Intellectual Property Organization. (2023). Patent Landscape Reports.
